Affordable Access

deepdyve-link
Publisher Website

Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution.

Authors
  • Barchiesi, Giacomo1, 2
  • McCartney, Amelia1
  • Biagioni, Chiara3
  • Siclari, Olimpia1
  • Rossi, Lorenzo1
  • Pestrin, Marta1
  • Di Leo, Angelo1
  • Biganzoli, Laura1
  • 1 Sandro Pitigliani" Department of Oncology, Ospedale Santo Stefano, Prato, Italy. , (Italy)
  • 2 IRCCS Regina Elena National Cancer Institute, Medical Oncology, Rome, Italy. , (Italy)
  • 3 Department of Oncology Bioinformatics Unit, Ospedale Santo Stefano, Prato, Italy. , (Italy)
Type
Published Article
Journal
The Breast Journal
Publisher
Wiley (Blackwell Publishing)
Publication Date
Nov 01, 2019
Volume
25
Issue
6
Pages
1225–1229
Identifiers
DOI: 10.1111/tbj.13437
PMID: 31310384
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Overall survival (OS), disease-free survival (DFS), and distant recurrence-free interval (DRFI) were evaluated from 169 patients diagnosed with early triple negative breast cancer. Overall, 5 and 10 years OS, DFS, and DRFI were 77% and 65%; 60% and 46%; and 74% and 73%, respectively. Forty-seven patients did not receive chemotherapy. A separate analysis was performed excluding those patients. In this subgroup, 5- and 10-year OS, DFS, and DRFI were 86% and 77%; 68% and 54%, 77% both at 5 and 10 years. Prognosis is better than previously described; adjuvant chemotherapy should be offered to fit elderly patients if clinically warranted. © 2019 Wiley Periodicals, Inc.

Report this publication

Statistics

Seen <100 times